XITONG WU: Open Payments
NPI 1609491984 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,378 in 76 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $70 · 2025 $1,378
Food & beverage: $1,359Education: $19
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $423 |
| Otsuka America Pharmaceutical, Inc. | 11 | $232 |
| Teva Pharmaceuticals USA, Inc. | 10 | $152 |
| Neurocrine BioSciences, Inc. | 5 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $86 |
| E.R. Squibb & Sons, L.L.C. | 3 | $78 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| Vanda Pharmaceuticals Inc. | 4 | $64 |
| Janssen Pharmaceuticals, Inc | 2 | $57 |
| Tris Pharma Inc | 2 | $33 |
Products named: VRAYLAR, INGREZZA, REXULTI, CAPLYTA, COBENFY, AUSTEDO XR, UZEDY, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
